日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia

扩增的、经历过抗原刺激的CD160(+)CD8(+)效应T细胞在慢性淋巴细胞白血病中表现出效应功能受损。

Bozorgmehr, Najmeh; Okoye, Isobel; Oyegbami, Olaide; Xu, Lai; Fontaine, Amelie; Cox-Kennett, Nanette; Larratt, Loree M; Hnatiuk, Mark; Fagarasanu, Andrei; Brandwein, Joseph; Peters, Anthea C; Elahi, Shokrollah

5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

在一项随机、III期临床试验中,氟达拉滨联合环磷酰胺(加或不加奥利美森)治疗复发或难治性慢性淋巴细胞白血病患者的5年生存率。

O'Brien, Susan; Moore, Joseph O; Boyd, Thomas E; Larratt, Loree M; Skotnicki, Aleksander B; Koziner, Benjamin; Chanan-Khan, Asher A; Seymour, John F; Gribben, John; Itri, Loretta M; Rai, Kanti R